A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma.

Daniel Chiu Jingjing Qi Tin Htwe Thin Monica Garcia-Barros Brian Hyohyoung Lee Mary Hahn John Mandeli Puneet B Belani Kambiz Nael Omid Rashidipour Saadi Ghatan Constantinos G Hadjipanayis Raymund L Yong Isabelle M Germano Rachel Brody Nadejda M Tsankova Sacha Gnjatic Seunghee Kim-Schulze Adília Hormigo

Published in: Cancer research communications (2023)

Our phase I of PD-L1 inhibition combined with LITT and using bevacizumab to spare steroids had a good safety profile for recurrent GBM. Developing combinatory treatment may help outcomes. In addition, we found significant immune modulation of cytokines and immune cells by bevacizumab, which may enhance the effect of ICI.

Keyphrases

metastatic colorectal cancer
study protocol
clinical trial
vascular endothelial growth factor
endothelial cells
skeletal muscle
randomized controlled trial
type diabetes
adipose tissue
insulin resistance
smoking cessation